Citation

BibTex format

@article{Cook:2019:10.1200/JCO.18.00501,
author = {Cook, LB and Fuji, S and Hermine, O and Bazarbachi, A and Ramos, JC and Ratner, L and Horwitz, S and Fields, P and Tanase, A and Bumbea, H and Cwynarski, K and Taylor, G and Waldmann, TA and Bittencourt, A and Marcais, A and Suarez, F and Sibon, D and Phillips, A and Lunning, M and Farid, R and Imaizumi, Y and Choi, I and Ishida, T and Ishitsuka, K and Fukushima, T and Uchimaru, K and Takaori-Kondo, A and Tokura, Y and Utsunomiya, A and Matsuoka, M and Tsukasaki, K and Watanabe, T},
doi = {10.1200/JCO.18.00501},
journal = {Journal of Clinical Oncology},
pages = {677--687},
title = {Revised adult T-cell Leukemia-Lymphoma international consensus meeting report},
url = {http://dx.doi.org/10.1200/JCO.18.00501},
volume = {37},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - PURPOSE: Adult T-cell leukemia-lymphoma (ATL) is a distinct mature T-cell malignancy caused by chronic infection with human T-lymphotropic virus type 1 with diverse clinical features and prognosis. ATL remains a challenging disease as a result of its diverse clinical features, multidrug resistance of malignant cells, frequent large tumor burden, hypercalcemia, and/or frequent opportunistic infection. In 2009, we published a consensus report to define prognostic factors, clinical subclassifications, treatment strategies, and response criteria. The 2009 consensus report has become the standard reference for clinical trials in ATL and a guide for clinical management. Since the last consensus there has been progress in the understanding of the molecular pathophysiology of ATL and risk-adapted treatment approaches. METHODS: Reflecting these advances, ATL researchers and clinicians joined together at the 18th International Conference on Human Retrovirology-Human T-Lymphotropic Virus and Related Retroviruses-in Tokyo, Japan, March, 2017, to review evidence for current clinical practice and to update the consensus with a new focus on the subtype classification of cutaneous ATL, CNS lesions in aggressive ATL, management of elderly or transplantation-ineligible patients, and treatment strategies that incorporate up-front allogeneic hematopoietic stem-cell transplantation and novel agents. RESULTS: As a result of lower-quality clinical evidence, a best practice approach was adopted and consensus statements agreed on by coauthors (> 90% agreement). CONCLUSION: This expert consensus highlights the need for additional clinical trials to develop novel standard therapies for the treatment of ATL.
AU  - Cook,LB
AU  - Fuji,S
AU  - Hermine,O
AU  - Bazarbachi,A
AU  - Ramos,JC
AU  - Ratner,L
AU  - Horwitz,S
AU  - Fields,P
AU  - Tanase,A
AU  - Bumbea,H
AU  - Cwynarski,K
AU  - Taylor,G
AU  - Waldmann,TA
AU  - Bittencourt,A
AU  - Marcais,A
AU  - Suarez,F
AU  - Sibon,D
AU  - Phillips,A
AU  - Lunning,M
AU  - Farid,R
AU  - Imaizumi,Y
AU  - Choi,I
AU  - Ishida,T
AU  - Ishitsuka,K
AU  - Fukushima,T
AU  - Uchimaru,K
AU  - Takaori-Kondo,A
AU  - Tokura,Y
AU  - Utsunomiya,A
AU  - Matsuoka,M
AU  - Tsukasaki,K
AU  - Watanabe,T
DO  - 10.1200/JCO.18.00501
EP  - 687
PY  - 2019///
SN  - 0732-183X
SP  - 677
TI  - Revised adult T-cell Leukemia-Lymphoma international consensus meeting report
T2  - Journal of Clinical Oncology
UR  - http://dx.doi.org/10.1200/JCO.18.00501
UR  - https://www.ncbi.nlm.nih.gov/pubmed/30657736
UR  - https://ascopubs.org/doi/pdf/10.1200/JCO.18.00501
VL  - 37
ER  -
Download